Koronis Pharmaceuticals
Koronis Pharma develops antiviral therapeutics based on a viral decay acceleration mechanism.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $55.0k | Debt | |
| Total Funding | 000k | ||
Related Content
Koronis Pharmaceuticals, established in Seattle in 1998, was a biotechnology firm focused on developing antiviral therapeutics. The company was acquired by Pacific Horizon Ventures in September 2016 and is now considered deadpooled. Over its operational history, the firm secured approximately $48 million in funding from investors including Asset Management Ventures, GeneChem, and Valhalla Private Capital.
The company's core technology was centered on a mechanism called Viral Decay Acceleration (VDA). This approach aimed to increase a virus's natural mutation rate to the point of causing the viral population to collapse. This was seen as a departure from conventional antiretroviral agents that work by inhibiting viral enzymes or proteins. The scientific origins of VDA are based on the work of researchers Larry Loeb, John Essigmann, and Jim Mullins, who operationalized a theory by Nobel laureate Manfred Eigen. The company acquired rights to this technology from the University of Washington.
Koronis's lead product candidate was KP-1461, an oral small-molecule therapeutic intended for the treatment of HIV. The company advanced KP-1461 into Phase 2 clinical trials to assess its safety and efficacy. Initial Phase 1b trials had shown the drug to be safe and well-tolerated. However, in October 2008, Koronis suspended the HIV trials due to concerns that the drug was not performing as expected. Beyond HIV, the company also had products in development for treating Hepatitis C and RSV.
The management team included Donald J. Elmer as interim CEO and Chairman, John Reno, Ph.D., as Chief Operating Officer, and Stephen Becker, M.D., as Chief Medical Officer. Dr. Reno brought over two decades of pharmaceutical development experience, while Dr. Becker had extensive experience in HIV clinical trials.
Keywords: antiviral therapeutics, Viral Decay Acceleration, VDA, HIV treatment, KP-1461, biotechnology, Hepatitis C, RSV, viral mutation, drug discovery, clinical trials, Seattle biotech, Pacific Horizon Ventures, acquired biotech, defunct biotech, pharmaceutical development, antiretroviral, viral population collapse, small-molecule therapeutic